We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » INDs, Postmarket Safety on FDA Rulemaking Agenda for 2017
INDs, Postmarket Safety on FDA Rulemaking Agenda for 2017
The FDA intends to publish a proposed rule that would replace current requirements for reports submitted on IND applications, according to an HHS inventory of agency rulemaking for 2017.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor